William Blair & Company
SEEL

William Blair & Company’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

William Blair & Company’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$46K – 2026
2021
Q4 		$46K Hold
7
– – ﹤0.01% 1786
2021
Q3 		$67K Buy
+7
New +$60.2K ﹤0.01% 1654

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

William Blair & Company's SEEL Position: Q1 2022 in Review

William Blair & Company sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022, closing a stake of 7 shares — an estimated $46K sold.

William Blair & Company first reported a position in SEEL in Q3 2021 and held it in 2 quarters. The position peaked at $67K in Q3 2021. 77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

  • William Blair & Company reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 7 Seelos Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $46K.
  • William Blair & Company first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • William Blair & Company's Seelos Therapeutics, Inc. Common Stock position peaked at $67K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.